Fact CheckerSign in

NCT05269589Recruiting

Home-based Heat Therapy for Type 2 Diabetes

Impact of a Home-based Heat Therapy Intervention on Markers of Cardiometabolic Function in Adults With Type 2 Diabetes

Source: ClinicalTrials.gov · Last updated 12 May 2026

Brief summary (registry, in English)

Insulin resistance and hyperglycemia predispose individuals with type 2 diabetes mellitus (T2DM) to endothelial dysfunction and a greater risk of cardiovascular diseases (CVD). Increased CVD risk in individuals with T2DM persists despite optimal pharmacological therapy, highlighting the need to identify complementary lifestyle interventions that improve cardiometabolic functions in this population. Evidence from animal models suggests that heat exposure improves metabolic functions. Notably, weekly heat exposure for 16 weeks blunts hyperinsulinemia and hyperglycemia induced by a high fat diet in mice. In parallel, studies in humans have shown that heat exposure improves vascular endothelial function. Based on such findings, it has been suggested that heat therapy may represent an effective lifestyle intervention to improve cardiometabolic functions. However, only 1 study has examined the impact of a heat therapy intervention on individuals with T2DM, demonstrating that 6 weeks of heat exposure reduces fasting plasma glucose and hemoglobin A1C. No study has considered potential vascular benefits of heat therapy in individuals with T2DM. This project will investigate cardiometabolic responses to repeated heat exposure in men and women with T2DM. We will test the hypothesis that 12 weeks of heat therapy improves postprandial fatty acid handling, insulin sensitivity and endothelial function in individuals with T2DM.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
44 (estimated)
First submitted
7 Feb 2022
Start date
18 Feb 2022
Primary completion date
Dec 2027
Lead sponsor
Montreal Heart Institute
NCT number
NCT05269589

What you commit to

  • Study type: Interventional
  • Planned participants: 44
  • From 18 Feb 2022 to the primary completion date, Dec 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Insulin therapy

Other illness

  • Hypertension not controled by medication
  • Diagnosis of cardiac, renal and/or pulmonary disease

Lab values

  • Fasting plasma triglycerides \>5.0 mmol/L
  • Fasting total cholesterol \>7 mmol/l

Other

  • Class 3 obesity
  • Diagnosis of severe neuropathy and/or retinopathy

Who the study is looking for

  • Age 45-75 years
  • Diagnosis of type 2 diabetes mellitus ≥1 year
  • Stable medication ≥12 weeks

Age in the registry: 45 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Centre ÉPIC, Montreal Heart Institute
Coordinator of this site? Confirm its status
MontrealCanadaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.